[1]
Nayak CA, Rastogi NK, Raghavarao KS. Bioactive constituents present in Garcinia indica choisy and its potential food applications: A review. Int J Food Prop 2010; 13: 441-53.
[2]
Baliga MS, Bhat HP, Pai RJ, Boloor R, Palatty PL. tde chemistry and medicinal uses of tde underutilized Indian fruit tree Garcinia indica Choisy (kokum): A review. Food Res Int 2011; 44: 1790-9.
[3]
Kunnumakkara AB, Koca C, Dey S, Gehlot P, Yodkeeree S, Danda D, et al. Molecular targets and tderapeutic uses of spices. New Jersey: World Scientific 2009; pp. 1-24.
[4]
Patel KJ, Panchasara AK, Barvaliya MJ, Purohit BM, Baxi SN, Vadgama VK, et al. Evaluation of cardio protective effect of aqueous extract of Garcinia indica Linn. Fruit rinds on isoprenaline-induced myocardial injury in Wistar albino Rats. RPS 2015; 10: 388.
[5]
Panda V, Ashar H, Srinatd S. Antioxidant and hepatoprotective effect of Garcinia indica fruit rind in etdanol induced hepatic damage in rodents. Interdiscip Toxicol 2012; 5: 207-13.
[6]
Antala BV, Patel MS, Bhuva SV, Gupta S, Rabadiya S, Lahkar M. Protective effect of metdanolic extract of Garcinia indica fruits in 6-OHDA rat model of Parkinson’s disease. Indian J Pharmacol 2012; 44: 83.
[7]
Lakshmi C, Kumar KA, Dennis TJ, Kumar TS. Antibacterial activity of polyphenols of Garcinia indica. Indian J Pharm Sci 2011; 73: 470.
[8]
Yamaguchi F, Saito M, Ariga T, Yoshimura Y, Nakazawa H. Free radical scavenging activity and antiulcer activity of garcinol from Garcinia indica fruit rind. J Agric Food Chem 2000; 48: 2320-5.
[9]
Govind PD, Aruna A, Nirupama D, Shipra D, Rajesh D, Mercy DS. A novel herbal formulation for tde prevention and management of type-2 diabetes mellitus and vascular complications associated witd diabetes WO2011158247 2011.
[10]
Amit P. Nutraceutical formulation for treatment of elevated cholesterol
and cardiovascular disease. US20140314729. (2014).
[11]
Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: A randomized controlled trial. JAMA 1998; 280: 1596-600.
[12]
Nayak CA, Srinivas P, Rastogi NK. Characterisation of antdocyanins from Garcinia indica Choisy. Food chemistry 2010; 118: 719-24.
[13]
Hegde MG, Goutdam N. Application of medicinal dye (turmeric and annatto) on silk fabrics using eco-friendly mordants. MSRUAS-SASTech J 2015; 14: 33-6.
[14]
Muhammed M. Anti-skin damage compositions with complimentary
dual mode of action. US2009169651 (2009).
[15]
Toshiaki A, Norio Y. Hyaluronidase inhibitor. JP2000072665. (2000).
[16]
Wang Y, Tsai ML, Chiou LY, Ho CT, Pan MH. Antitumor activity of garcinol in human prostate cancer cells and xenograft mice. J Agric Food Chem 2015; 63: 9047-52.
[17]
Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS. Induction of p21Waf1/Cip1 by garcinol via down regulation of p38-MAPK signalling in p53-independent H1299 lung cancer. J Agric Food Chem 2014; 62: 2085-95.
[18]
Hong J, Sang S, Park HJ, Kwon SJ, Suh N, Huang MT, et al. Modulation of arachidonic acid metabolism and nitric oxide syntdesis by garcinol and its derivatives. Carcinogenesis 2006; 27: 278-86.
[19]
Koeberle A, Nortdoff H, Werz O. Identification of 5-lipoxygenase and microsomal prostaglandin E2 syntdase-1 as functional targets of tde anti-inflammatory and anti-carcinogenic garcinol. Biochem Pharmacol 2009; 77: 1513-21.
[20]
Hung WL, Liu CM, Lai CS, Ho CT, Pan MH. Inhibitory effect of garcinol against 12-O-tetradecanoylphorbol 13-acetate-induced skin inflammation and tumorigenesis in mice. J Funct Foods 2015; 18: 432-44.
[21]
Toshiaki A, Shigehiro K, Koichi K, Akira M, Norio Y. Antitumor agent. PH11139965 (1999).
[22]
Kundu TK, Karnam B, Kempegowda M, Altaf M, Venkatesh S, Radhika AV. Polyisoprenylated benzophenones and their iso
mers as inhibitors of histone acetyltransferases and uses thereof.
US7402706 2008.
[23]
Padhye S, Ahmad A, Oswal N, Sarkar FH. Emerging role of Garcinol, tde antioxidant chalcone from Garcinia indica Choisy and its syntdetic analogs. J Hematol Oncol 2009; 2: 1.
[24]
Tang W, Pan MH, Sang S, Li S, Ho CT. Garcinol from Garcinia indica: Chemistry and Healtd Beneficial Effects.In: Patil BS,
Jayaprakasha GK, Roa CO, Mahattanatawee K, Eds. . Tropical and subtropical fruits: Flavors, color, and healtd benefits. Washington, DC: American Chemical Society 2013; pp. 33-145.
[25]
Won SJ, Liu CT, Tsao LT, Weng JR, Ko HH, Wang JP, et al. Syntdetic chalcones as potential anti-inflammatory and cancer chemo preventive agents. Eur J Med Chem 2005; 40: 103-12.
[26]
O’Dell JR. tderapeutic strategies for rheumatoid artdritis. N Engl J Med 2004; 350: 2591-602.
[27]
Ruiz-Esquide V, Sanmartí R. Tobacco and otder environmental risk factors in rheumatoid artdritis. Reumatol Clin 2012; 8(6): 342-50.
[28]
Phull AR, Nasir B, Haq IU, Kim SJ. Oxidative stress, consequences and ROS mediated cellular signaling in rheumatoid artdritis. Chem Biol Interact 2018; 281: 121-36.
[29]
Taneja V. Artdritis susceptibility and tde gut microbiome. FEBS Lett 2014; 588(22): 4244-9.
[30]
Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid artdritis. Best Pract Res Clin Rheumatol 2017; 31(1): 3-18.
[31]
Goulielmos GN, Zervou MI, Myrtdianou E, Burska A, Niewold TB, Ponchel F. Genetic data: tde new challenge of personalized medicine, insights for rheumatoid artdritis patients. Gene 2016; 583(2): 90-101.
[32]
Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, et al. An overview of economic evaluations for drugs used in rheumatoid artdritis: Focus on tumour necrosis factor-alpha antagonists. Drugs 2005; 65: 473-96.
[33]
Banarjee S, Parsramka MA, Parutdy SB. Garcinol: Preclinical
Perspective Underpinning Chemo- and Radiosensitization of Cancer.In: Bharti AC, Aggarwal BB, Eds. Role of Nutraceuticals in
Cancer Chemosensitization Volume 2 in Cancer Sensitizing Agents
for Chemotherapy. In: United States, Academic Press 2018; pp. 297-324.
[34]
Liu C, Ho PC, Wong FC, Setdi G, Wang LZ, Goh BC. Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects. Cancer Lett 2015; 362(1): 8-14.
[35]
Vogel HG. Drug discovery and Evaluation Pharmacological Assay. 2nd ed. Springer: Germany 2002.
[36]
Costa MD, De Sutter P, Gybels J, Van Hees J. Adjuvant-induced artdritis in rats: A possible animal model of chronic pain. Pain 1981; 10(2): 173-85.
[37]
Kumar VL, Roy S, Sehgal R, Padhy BM. A comparative study on tde efficacy of rofecoxib in monoarticular artdritis induced by latex of Calotropis procera and Freund’s complete adjuvant. Inflammopharmacology 2006; 14: 17-21.
[38]
Hoogstraate J, Andersson LI, Berge OG, Jonzon B, Öjteg G. COX-inhibiting nitric oxide donators (CINODs): A new paradigm in tde treatment of pain and inflammation. Inflammopharmacology 2003; 11: 423-8.
[39]
Liu YL, Lin HM, Zou R, Wu JC, Han R, Raymond LN, et al. Suppression of complete Freund’s adjuvant-induced adjuvant artdritis by cobratoxin. Acta Pharmacol Sin 2009; 30: 219-27.
[40]
Tak PP, Firestein GS. NF-κB: A key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
[41]
Roman-Blas JA, Jimenez SA. NF-κB as a potential tderapeutic target in steoartdritis and rheumatoid artdritis. Osteoartdritis Cartilage 2006; 14: 839-48.
[42]
Wang S, Wang Y, Liu X, Guan L, Yu L, Zhang X. Anti-inflammatory and anti-artdritic effects of taraxasterol on adjuvant-induced artdritis in rats. J Etdnopharmacol 2016; 187: 42-8.
[43]
Toshiaki A, Norio Y. Lipase inhibitor and antiobestic medicine or
hyperlipidemia inhibitor. JP2000044468. (2000).
[44]
Muhammed M, Vladimir B. . Composition comprising hydroxycitric
acid and garcinol for weight-loss. EP1254209. (2006).
[45]
Ann MO, Brendan JO. Appetite suppressant composition and
method of appetite suppression. US20090062231 . (2009).
[46]
Muhammed M. Compositions and its use in treating obesity or
inducing weight loss. US8329743 (2012).
[47]
Muhammed M, Sarang B. Hepatoprotectant activity of garcinol.
US20130281544 (2013).
[48]
Gaurang SD. Methods and materials for treating endometriosis.
WO2016123044. (2016).
[49]
Sonia G, Srinivasan BP. Effect of garcinol in delaying the progression
of diabetic nephropathy. US9872840. (2016).
[50]
Sandip B, Ajay K, Jaideep B, et al. Polyprenylated phloroglucinol
compounds as potent p-glycoprotein inducers. WO2016063296. (2016).
[51]
Sunil B, Moharn V. Complex of garcinol, cyclodextrin and
method thereof. US9956301 (2018).
22
3
1
1